Neurodermatitis

Summary

Neurodermatitis (MONDO:0006585) is a disease and 15 clinical trials. Top therapeutic interventions include dupilumab, betamethasone valerate, and gamolenic acid. A subtype of dermatitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 15

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	neurodermatitis
Mondo ID	MONDO:0006585
EFO	EFO:1000740
MeSH	D009450
DOID	DOID:3309
ICD-10-CM	L28.0
NCIT	C111963
SNOMED CT	267854005
UMLS	C0027822
MedGen	45056
Is cancer (heuristic)	no

Also known as: lichen simplex Chronicus

Disease family

This is a subtype of dermatitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › dermatitis › neurodermatitis

Related subtypes (32): spongiotic dermatitis, atopic eczema, psoriasis, contact dermatitis, urticaria, acneiform dermatitis, acrodermatitis, folliculitis, granuloma annulare, granulomatous dermatitis, lichen planus, neurotic excoriation, parapsoriasis, pityriasis rosea, seborrheic dermatitis, acanthosis nigricans, dermatosis papulosa nigra, lichen sclerosus et atrophicus, vitiligo, acne, porphyria cutanea tarda, dermatomyositis, acute generalized exanthematous pustulosis, hydroa vacciniforme, autoimmune bullous skin disease, cutaneous vasculitis, skin infection, intertrigo, lipodermatosclerosis, exfoliative dermatitis, radiodermatitis, food dermatitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Dupilumab	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 15.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	5
Not specified	5
PHASE4	2
PHASE1	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00878670	PHASE4	COMPLETED	Investigation of Efficacy and Safety of EPOGAM
NCT03630198	PHASE4	COMPLETED	Pain Outcomes Following Intralesional Corticosteroid Injections
NCT06687967	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)
NCT06687980	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)
NCT00196430	PHASE3	COMPLETED	Study About Effectiveness of Silver-Containing Textiles for Treatment of Acute Neurodermatitis
NCT04183335	PHASE3	COMPLETED	Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)
NCT04202679	PHASE3	COMPLETED	Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)
NCT03858634	PHASE2	COMPLETED	A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases
NCT07013097	PHASE1	RECRUITING	A Phase I Clinical Trial to Evaluate the Single Dose Ascending and Food Effects of PG-033 in Healthy Adults
NCT05454462	PHASE1	COMPLETED	KM-001 Cream for Treatment of Pruritus in Adult Patients With Lichen Simplex Chronicus (LSC)
NCT07580911	Not specified	NOT_YET_RECRUITING	Efficacy and Safety of HA35 Gel for Ultra-Rapid Skin Pruritus Relief
NCT02732145	Not specified	COMPLETED	Diagnostic Accuracy of Three Rings Vulvoscopy for Detection of Vulvar Dermatosis
NCT05770271	Not specified	COMPLETED	The Novel Electrolyzed Water Spray Treatment Mild Senile Groin Eczema, Neurodermatitis and Psoriasis
NCT06267066	Not specified	UNKNOWN	Fractional Carbon Dioxide Laser: A Novel Therapeutic Option for Lichen Simplex Chronicus
NCT07206680	Not specified	COMPLETED	Effect of Extracorporeal Shockwave Therapy on Pruritus in Neurodermatitis Patients

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DUPILUMAB	4	4
BETAMETHASONE VALERATE	4	1
GAMOLENIC ACID	3	1
VIXARELIMAB	2	1